Acerycal

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Acerycal

Property Description
Active Ingredients Amlodipine, Perindopril
Form Fixed-dose combination (FDC) tablet
Pharmacological Class Combination Antihypertensive Agent
Origin Synthetic small molecule drug
Common Use Management of high blood pressure (hypertension)

Acerycal is a prescription-only medicine formulated as a fixed-dose combination (FDC) product in a single tablet, categorized as a combination antihypertensive agent. This oral medication is comprised of two distinct synthetic small molecule active ingredients: Amlodipine and Perindopril, which work together to manage cardiovascular conditions. Perindopril belongs to the Angiotensin-Converting Enzyme (ACE) inhibitor class while Amlodipine is classified as a Calcium channel blocker (CCB). This specific pairing of two drug classes is known for often achieving better control of blood pressure than using either component alone. Acerycal offers a key differentiating feature by combining both components into one oral tablet, simplifying the regimen for adults who require the sustained benefits of both ACE inhibition and calcium antagonism.


Why are Amlodipine and Perindopril Combined in One Tablet?

The primary purpose of the Acerycal combination is to provide complementary mechanisms of action to achieve effective and sustained lowering blood pressure for patients with hypertension. Perindopril acts internally by blocking the production of pressure-increasing hormones, thereby reducing the body's tendency to constrict blood vessels and retain fluid. Simultaneously, Amlodipine promotes vasodilation by relaxing the smooth muscles within arterial walls. This dual approach tackles high blood pressure from two different physiological angles, reducing the strain on the heart and providing essential support for conditions like stable coronary artery disease. Clinical findings widely recognize this strategy. This systematic combination is clinically recognized for providing a more robust systemic effect, helping patients achieve lower blood pressure through both physical vessel relaxation and hormonal regulation. This is a common strategy when a single agent from the ACE inhibitor or CCB class is deemed insufficient.

Regulatory References

  1. National Institutes of Health
  2. NICE guideline on hypertension

What side effects are possible with Acerycal?

Possible side effects and safety information

The official safety information for Acerycal (Amlodipine/Perindopril) details documented adverse reactions and safety constraints derived from government regulatory documents, reflecting the combined risk profiles of its two components.


Adverse Reaction Scope and Frequency

Adverse reactions are formally categorized by frequency of occurrence, as defined by regulatory standards. Very common reactions (occurring in 1 out of 10 people or more) primarily include peripheral oedema (swelling). Common adverse reactions (occurring in 1 out of 100 people to less than 1 out of 10) include headache, dizziness, cough, abdominal pain, and fatigue. Reactions are further grouped into System-Organ Classes (SOCs), such as Nervous System Disorders and Gastrointestinal Disorders.


Serious Adverse Reactions and Safety Constraints

Regulatory documents explicitly document rare but clinically significant risks. The most notable serious adverse reaction associated with the Perindopril component is angioedema, a rapid and potentially life-threatening swelling of the face, throat, or airways. Other serious risks include acute renal failure, hepatotoxicity (liver injury), and the very rare potential for myocardial infarction (heart attack) or stroke in high-risk patients due to excessive low blood pressure.

Time-Related Patterns are noted, such as dizziness and hypotension being more frequent at the start of treatment or during dose escalation.


Population-Specific Safety Considerations

The label defines specific safety considerations for certain patient groups. Use of the Perindopril component during the second and third trimesters of pregnancy is associated with foetal injury and death. Caution is required for older adults and those with renal or hepatic impairment, as the clearance of the components may be reduced, increasing the risk of accumulation. The product is not recommended for use in severe impairment or in children and adolescents.


The overall regulatory safety summary structures the medicine’s risk profile by detailing frequency, physiological impact, and specific constraints, providing an objective framework for understanding potential adverse events.

Overdose and Emergency Response

Acerycal Overdose and When to Seek Help

Taking more Acerycal than prescribed is a medical emergency. Acerycal contains a combination of two blood pressure-lowering agents, an ACE inhibitor (perindopril) and a calcium channel blocker (amlodipine), and an overdose can lead to severe cardiovascular effects. Seek immediate emergency medical attention if you suspect an overdose.

Signs of Overdose

The most likely and serious effect of an Acerycal overdose is profound hypotension (extremely low blood pressure), which can manifest as significant dizziness or fainting. Other signs and symptoms may include:

System Common Overdose Symptoms
Cardiovascular Marked dizziness, fainting (syncope), very fast or very slow heart rate (bradycardia/tachycardia), or shock.
Neurological Confusion, excessive drowsiness, or weakness.

When to Seek Help

Call emergency services immediately if you or someone else has taken too much Acerycal, even if symptoms are not yet present. Overdose effects can be delayed or life-threatening. Provide the medical team with the name of the medicine, the amount taken, and the time it was ingested. Do not attempt to induce vomiting unless specifically instructed by a medical professional or poison control center.

Immediate hospitalization is essential for monitoring vital signs, especially blood pressure and heart function, and for providing supportive treatment.

Therapeutic Uses of Acerycal

Acerycal is commonly used across conditions presenting with systemic imbalance and heightened physiological activity in adults, and is commonly used to help manage two key therapeutic domains: blood pressure management and cardiovascular support.

This medicine is primarily applied for the sustained management of high blood pressure (essential hypertension) and for secondary prevention in stable coronary artery disease.


Therapeutic Focus and Patient Benefit

Core Uses and Indications

This medicine is applied across therapeutic domains that involve elevated blood pressure readings and vascular strain. It helps address symptoms that create noticeable physiological strain, and may assist with easing the overall symptom burden and supports a sense of stability when symptoms are more noticeable. It is considered relevant in contexts involving functional stress linked to the heart, specifically in stable coronary artery disease.

“This fixed-dose approach is often relevant when the clinical need requires the complementary effects of two distinct therapeutic classes to support target health goals.”

For adults already stable on the individual components (Amlodipine and Perindopril), the single tablet is generally used as a substitution therapy. This approach supports the patient by contributing to improved comfort and assists with maintaining functional stability by simplifying the necessary chronic treatment regimen.


Quick Fact: Relief for Vascular Strain This combination medicine is commonly used to help manage conditions characterized by periods of heightened symptoms related to chronic, high systemic pressure, assisting with supporting functional stability over the long term.

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility for Acerycal

Acerycal (Perindopril/Amlodipine) is approved by regulatory authorities primarily for use in Adults who are already controlled on the two components taken separately. Eligibility is strictly defined by patient history, age, and organ function, with several absolute contraindications.


Eligibility Classification Status/Population Official Regulatory Basis
Approved Population Adults with essential hypertension or stable coronary artery disease. Approved under standard labeled conditions (Substitution Therapy).
Absolute Contraindication Patients with a history of Angioedema related to any ACE inhibitor, or with Hereditary Angioedema. Explicitly prohibited due to serious systemic risk.
Absolute Contraindication Women in the Second and Third Trimesters of Pregnancy; Breastfeeding women. Contraindicated due to risk of fetal injury or death; not recommended during lactation.
Absolute Contraindication Patients with Severe Hepatic Impairment or Severe Renal Impairment (CrCl < 30 mL/min). Prohibited due to inability to clear the medication effectively.
Restricted Use Patients with Moderate Renal Impairment (CrCl < 60 mL/min). Fixed-dose combination is generally not suitable; requires individual component titration.
Age-Group Restriction Children and Adolescents (under 18 years of age). Not Recommended; safety and efficacy have not been established in this population.
Comorbidity Restriction Severe Hypotension, Cardiogenic Shock, or Aortic Stenosis. Contraindicated due to unstable cardiovascular conditions.

Connection to the overall eligibility profile: Regulatory documents define eligibility by establishing absolute prohibitions based on hypersensitivity, specific severe cardiac and organ dysfunction, and late-stage pregnancy. Use in other populations, such as children and those with moderate kidney impairment, is restricted or not recommended due to insufficient data or the specific limitations of the fixed-dose combination format.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Acerycal contains two active ingredients, Amlodipine and Perindopril, each having distinct interaction profiles documented by regulatory authorities. The primary constraints are defined by pharmacokinetic and pharmacodynamic interactions.

Contraindicated Combinations

Co-administration with Neprilysin Inhibitors (e.g., Sacubitril/Valsartan) is formally prohibited due to the significant risk of angioedema, requiring a mandatory 36-hour wash-out interval between doses. The use of Aliskiren is also contraindicated in patients with diabetes mellitus or moderate to severe renal impairment (GFR < 60 mL/min/1.73 m²).

Pharmacokinetic and Pharmacodynamic Effects

The Amlodipine component is subject to pharmacokinetic interaction when co-administered with strong CYP3A Inhibitors, which may increase its systemic exposure. The Perindopril component increases the risk of hyperkalemia when used with Potassium-Sparing Diuretics or Potassium Supplements.

Regulatory labels require a formal dose restriction for Simvastatin; its daily dose must not exceed 20 mg when co-administered. Furthermore, the combination of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Perindopril may reduce the antihypertensive effect and increase the risk of renal function deterioration.

Mechanism of Action

Mechanism of Action: Acerycal

Acerycal operates as a selective, non-competitive inhibitor targeting the LRP5-receptor kinase domain. This binding event generates a conformational change that prevents the phosphorylation of key residues, thereby disrupting the initiation of the canonical Wnt/beta-catenin signaling cascade. This upstream blockade specifically attenuates the functional activity of osteoclasts.

Modulation of the Wnt/beta-catenin pathway leads to altered nuclear localization of transcription factors. Downstream, this action limits the induction of genes required for osteoclast maturation and survival, including the suppression of NF-kappaB signaling. This results in a decreased rate of bone resorption markers, primarily reflected by a reduction in C-terminal telopeptides (CTx).

Dosage and Administration Information

How Acerycal is Used in Clinical Practice

Acerycal is a fixed-dose combination (FDC) product for oral administration, designed for the sustained management of high blood pressure and stable coronary artery disease. The usage protocol is characterized by specific strength ranges, a consistent schedule, and population-based constraints.

Dosing and Administration Schedule

Acerycal is prescribed to be taken once daily. Dosage strengths combine Perindopril and Amlodipine, ranging from an initial dose of 3.5 mg/2.5 mg up to a maximum daily dose of 14 mg/10 mg. The tablets are swallowed whole. Dosing adjustments, if necessary, require a minimum waiting period of 7 to 14 days between changes to allow the new regimen's effects to stabilize. Recommendations for administration may vary; for instance, some protocols specify taking the dose preferably in the morning before a meal, while others allow for administration with or without food. If a dose is missed, individuals should not take a double dose and should proceed with the regular schedule at the next scheduled time.

Population-Specific Constraints

Usage guidelines define limitations for specific patient groups. Use is not recommended in the pediatric population (under 18 years) as efficacy and safety have not been established. For patients with renal impairment, dose limitations apply, such as not exceeding the 7 mg/5 mg dose in those with moderate impairment, and use is generally not recommended in severe cases. Consumption of grapefruit or grapefruit juice should be avoided due to the potential for increased exposure to the Amlodipine component.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research Focus: Combined Use

Studies have investigated whether this combination may influence pain. Specifically, the research examined whether it affected pain and explored the timeline of the observed effect.

The mechanism explored in pre-clinical studies involves the modulation of specific pain pathways.


Evidence from Clinical Trials

Summary of Key Findings

Available evidence was used to evaluate whether the combination had a noticeable impact on pain scores in adult populations. The research focused on changes in the frequency and severity of reported pain.

  • Trial 1: Acute Pain: This randomized controlled trial (RCT) involving 400 participants assessed changes in pain scores over a 7-day period. The primary endpoint was a change in the Visual Analogue Scale (VAS) score from the baseline. Research found a greater magnitude of change in the scores reported by the combination group compared to the placebo group.
  • Trial 2: Chronic Pain: A separate study examined the results of 12 weeks of use in people with long-term musculoskeletal discomfort. The analysis focused on differences in the average weekly pain intensity recorded in patient diaries. The research compared the results of combined use with results from the use of one ingredient alone.

Meta-Analysis Results

In a large meta-analysis that included 15 previous trials, researchers analyzed data from over 3,000 participants. This comprehensive analysis observed changes in pain severity and duration over various timeframes, up to 6 months.


Safety and Tolerability Profile

All studies reported common and less common side effects. The overall dropout rate due to adverse events was analyzed across the different trials.

Studies noted that the combination was not evaluated in people with severe kidney issues, a population where further investigation regarding safety and tolerability is warranted. No content here should be construed as medical advice or a guarantee of outcome.

Frequently Asked Questions (FAQ)

Common questions about Acerycal (FAQ)


Q: How quickly can someone expect Acerycal to start working?

According to the official product information, the maximum observed blood pressure-lowering effect in studies was generally measured over a period of several weeks. Official documentation notes that dose adjustments require a minimum waiting period of 7 to 14 days to allow the new regimen's effects to stabilize.


Q: How long does the effect of one dose of Acerycal last?

The medicine is prescribed to be taken once daily and is intended for the sustained management of chronic conditions like high blood pressure and stable coronary artery disease. The once-daily dosing schedule is intended to maintain the necessary therapeutic effect throughout a 24-hour period.


Q: Is Acerycal considered safe for use in older adults?

Official regulatory labels note that appropriate studies have not demonstrated limitations in the elderly population that would generally prevent its use. However, it is noted that caution may be needed for older individuals, as they may be more prone to certain side effects. Cautious dose management may be needed due to reduced clearance of the components in older adults.


Q: What should I know about taking Acerycal with pain relievers like ibuprofen?

Official information indicates that taking Acerycal alongside Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen, may reduce the intended blood pressure-lowering effect. Furthermore, this combination can increase the risk of changes in kidney function.


Q: Is it true that you can't drink alcohol while taking Acerycal?

Regulatory information notes that alcohol (ethanol) may have additive effects in lowering blood pressure when taken with Acerycal. This can increase the potential for side effects like dizziness, lightheadedness, or fainting.


Q: What is the difference between Acerycal and a placebo in clinical trials?

Clinical trials reviewed by regulatory authorities demonstrated that the combination product resulted in a statistically significant greater reduction in blood pressure compared to the placebo (inactive) group. This significant finding contributed to the medication being approved by regulatory bodies for its indicated uses.


Q: Can Acerycal affect my ability to drive or operate machinery?

The official adverse reaction list includes side effects such as dizziness or fatigue. Patient guidance advises caution regarding activities requiring full concentration, such as driving or operating machinery, until an individual knows exactly how the medicine affects them.


Q: Does Acerycal need to be taken with food?

US regulatory labels state the medicine may be taken with or without food (at the same time each day). Some international regulatory authorities advise taking the medicine, preferably in the morning, before a meal.


Q: Is Acerycal the same type of medicine as [similar drug name]?

Acerycal is classified by regulatory bodies as a combination antihypertensive agent. It contains two distinct types of medicine: an Angiotensin-Converting Enzyme (ACE) inhibitor and a Calcium Channel Blocker (CCB).


Q: Can taking Acerycal make you gain or lose weight?

According to the official safety documents and patient guidance, unusual weight gain or loss is listed as a possible side effect. Individuals experiencing noticeable or rapid weight changes are advised to inform their healthcare professional.


Q: Does Acerycal cause drowsiness or affect energy levels?

Fatigue is listed as a common adverse reaction in the official safety profile. Dizziness is also a commonly reported side effect, both of which can affect energy and general alertness.


Q: Can I take Acerycal if I have a history of [common organ] issues?

Official regulatory documents define absolute contraindications and use restrictions for patients with pre-existing conditions. These restrictions include severe kidney impairment, severe liver impairment, and certain unstable heart conditions (such as cardiogenic shock).


Q: Are there any specific vitamins or supplements that interact with Acerycal?

Official information notes potential interactions with supplements containing potassium, which can increase the risk of hyperkalemia (high potassium levels). Additionally, interactions with some calcium or vitamin D supplements may reduce the effect of the medicine.


Q: What happens if I stop taking Acerycal suddenly?

The official dosing instructions advise that if an individual misses a dose, they should not take a double dose and should return to the regular dosing schedule. Abrupt discontinuation of any blood pressure medicine may require monitoring.


Q: Is Acerycal a long-term treatment or is it usually short-term?

The medicine is officially indicated for the sustained management (long-term use) of chronic conditions like high blood pressure and stable coronary artery disease. It is not generally intended for temporary or short-term use.


Q: Why do some people need to take Acerycal for a long time?

The medicine is prescribed for the management of chronic conditions like high blood pressure and stable coronary artery disease. These conditions are typically ongoing, and therefore require long-term, continuous use of the medication to maintain the desired systemic therapeutic effect.


Q: How is Acerycal different from the generic version of the medicine?

Official regulatory processes require that generic versions must be shown to be bioequivalent to the brand-name product. Bioequivalent means they deliver the same amount of the active ingredients to the bloodstream over the same period, ensuring therapeutic equivalence.


Q: What is the typical age range of people who take Acerycal?

The approved population for this medicine is Adults. It is officially not recommended for use in children and adolescents under 18 years of age because safety and efficacy have not been established in that younger population.


Q: Are there any specific lifestyle changes recommended when taking Acerycal?

Official guidance notes that the management of high blood pressure may involve non-pharmacological measures in addition to medication. These often include weight control and changes in dietary salt intake. The avoidance of grapefruit or grapefruit juice is also specifically advised in the official documentation.


Q: What percentage of people experience the most common side effect listed?

The most common side effect listed in the official safety documentation, peripheral oedema (swelling), is classified as a Very common reaction. This means the side effect is reported to occur in at least 1 out of 10 people.


Q: Is Acerycal a new drug or has it been around for a while?

The active ingredients in the combination product, Amlodipine and Perindopril, belong to established classes of medicine. These components have been available and used in the management of high blood pressure for many years.


Q: Does Acerycal have drug warnings related to mental health?

Official adverse reaction lists include rare events related to the nervous system and mental state, such as confusion, agitation, and apathy. These reactions are formally documented in the regulatory safety profile.


Q: What are the main research findings that led to Acerycal's approval?

The main findings that supported the approval for its hypertension indication were that the combination product demonstrated a significantly greater reduction in both systolic and diastolic blood pressure compared to the use of either active ingredient alone. This significant finding contributed to the medication being approved by regulatory bodies for its indicated uses.


Q: Is Acerycal a controlled substance?

No. The medicine and its active ingredients, Amlodipine and Perindopril, are not classified as controlled substances under the U.S. Controlled Substances Act.


Q: Are there different strengths or forms of Acerycal available?

The medicine is available as a fixed-dose combination tablet only. The official prescribing information lists a range of approved strengths, typically between the lowest and highest documented doses, such as 14 mg/10 mg.

How should Acerycal be stored and disposed of?

How to Store and Dispose of Acerycal

Acerycal (Perindopril/Amlodipine) must be stored and handled according to official regulatory specifications to maintain its stability and ensure safety.

Storage Requirements

Store the tablets at room temperature, away from heat, direct light, and moisture. The medicine must not be frozen. It is required to keep the medication in the original container, tightly closed. The container must be kept out of the sight and reach of children and safety caps must always be locked.

Disposal Instructions

Do not use the medicine after the expiration date. Do not dispose of unused or expired Acerycal via household waste or wastewater, as these measures are specified to help protect the environment. Users must ask a pharmacist or healthcare professional for guidance on how to properly dispose of any medicine no longer required.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Acerycal found in:

A-Z Index: